AlloVir, Inc. (NASDAQ:ALVR) Stake Lowered by Two Sigma Investments LP

Two Sigma Investments LP trimmed its stake in shares of AlloVir, Inc. (NASDAQ:ALVR) by 9.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 266,587 shares of the company’s stock after selling 28,574 shares during the quarter. Two Sigma Investments LP owned about 5.30% of AlloVir worth $112,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in ALVR. Raymond James Financial Inc. bought a new position in AlloVir during the 4th quarter worth $25,000. BNP Paribas Financial Markets acquired a new position in shares of AlloVir during the fourth quarter valued at $31,000. Jane Street Group LLC boosted its holdings in shares of AlloVir by 47.8% during the fourth quarter. Jane Street Group LLC now owns 123,159 shares of the company’s stock valued at $52,000 after acquiring an additional 39,808 shares during the period. Northern Trust Corp grew its position in shares of AlloVir by 0.8% during the fourth quarter. Northern Trust Corp now owns 159,685 shares of the company’s stock worth $67,000 after acquiring an additional 1,267 shares during the last quarter. Finally, Tang Capital Management LLC acquired a new stake in shares of AlloVir in the 4th quarter worth about $232,000. Institutional investors own 66.05% of the company’s stock.

AlloVir Stock Down 5.8%

Shares of NASDAQ:ALVR opened at $2.90 on Friday. The company’s 50-day moving average price is $4.84 and its 200 day moving average price is $8.26. The company has a market cap of $14.62 million, a PE ratio of -0.14 and a beta of 0.63. AlloVir, Inc. has a fifty-two week low of $7.96 and a fifty-two week high of $24.15.

AlloVir Profile

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.